Dr. Philip Mease: Risankizumab in PsA
Agree. Only 6% were strong recommendations. Glad they addressed comorbidities but management not necessarily consistent with my current practice pic.twitter.com/reUg9ktFwS
— Julio Gonzalez (@japaoli19) November 9, 2017
New PsA guideline expected in 2018. #ACR17 https://t.co/c7Y8GiBv4q pic.twitter.com/g7wtIBXXko
— Rheumatology News (@rheumnews1) November 9, 2017
Smoking paradox: smoking assoc w/⬆️risk of PsA in gen population HR1.27 but w/ ⬇️risk of PsA in PSO (HR 0.91) population-based study concludes https://t.co/TfKFThRsJX @RheumNow
— Olga Petryna (@DrPetryna) November 9, 2017
Dr. Shashank Akerkar: New Molecules in Psoriatic Arthritis
Come do Orange Theory w/ me! High intensity interval training may improve fatigue in PsA pts. #ACR17 @RheumNow #2968 https://t.co/il89TsLIwY pic.twitter.com/smAg512J8Z
— Dr. Rachel Tate (@uptoTate) November 8, 2017
New ACR/NPF guidelines just presented#ACR17 @RheumNow pic.twitter.com/dnc0r6bp7U
— Julio Gonzalez (@japaoli19) November 7, 2017
Dr. Julio Gonzalez: Radiographic Progression in Psoriatic Arthritis
Ustekinumab shows clinical benefit in SLE – SRI-4 response at Wk 24 was significantly better than placebo (∆ 29%) #ACR17 late breaking abstracts https://t.co/Q1cLdTjhWv
— Hector Chinoy (@drhectorchinoy) November 8, 2017
Dr. Philip Mease: FUTURE 5 Study
Poster title of the day….! #2556 @RheumNow #ACR17 pic.twitter.com/nDmsAQQS19
— Ian N Bruce (@Lupusdoc) November 7, 2017
Dr. Mease presenting late breaking abstract 17L on secukinumab and delaying radiographic progression in PsA. #ACR17 @rheumnow pic.twitter.com/jhuiT97P2i
— Dr. Rachel Tate (@uptoTate) November 7, 2017
Diagnostic, elemental ultrasonographic abnormalities in PsA. Possible diagnostic criteria? #ACR17 @RheumNow #1874 https://t.co/CbXjY4JGCm pic.twitter.com/nkymcumXR5
— Dr. Rachel Tate (@uptoTate) November 7, 2017
Dr. Olga Petryna: Cardiovascular Comorbidities
RheumNow coverage of ACR 2017 mtg is sponsored by Novartis. All content chosen by RheumNow Faculty https://t.co/vpjgyXpHXA
— Dr. John Cush (@RheumNow) November 7, 2017
What is your 1st line, post DMARD, treatment of advanced active PsA? #ACR17 @RheumNow
— Dr. Rachel Tate (@uptoTate) November 6, 2017
Persistence of MTX at week 24 in PSA is 83%. Not as bad as some people make out #ACR17 @RheumNow Abs 1252 pic.twitter.com/Dbw2cFwVIX
— Philip Robinson (@philipcrobinson) November 6, 2017
Collaborative ACR/NPF effort yields new clinical guideline for treatment of adult patients w/ active PsA. https://t.co/uw1VFWDqB2 #ACR17 pic.twitter.com/lJEYo1BEoN
— AmerCollRheumatology (@ACRheum) November 6, 2017
Cosentyx significantly improves ACR scores in PsA up to wk156, better in high CRP group #1523 #ACR17 @RheumNow pic.twitter.com/KgLIL74jKg
— Olga Petryna (@DrPetryna) November 6, 2017
Tofa ⬇️ radiograph progression in PsA, better in pts w/low CRP.>90% pts non-progression at 12mo @RheumNow #acr17 #880 pic.twitter.com/l3YeejkJiY
— Olga Petryna (@DrPetryna) November 6, 2017
Secukinumab meets T2T endpoints in PsA.Early onset did better. Should we measure in clinic?#ACR17 @RheumNow #622 pic.twitter.com/SchOSRVqKT
— Julio Gonzalez (@japaoli19) November 6, 2017
UST tops TNFi resolving enthesitis in a small sample of PsA pts. ECLIPSA
#881#ACR17 @RheumNow https://t.co/5AKRP473dD pic.twitter.com/bZOLWsQnIG— Julio Gonzalez (@japaoli19) November 5, 2017
>90% PsA patients showed no radiologic progression at 12 months on Tofacitinib Desiree Van Der Heijde #880 #ACR17 @RheumNow
— Dr. shashank akerkar (@doctorakerkar) November 5, 2017
Novartis has sponsored expanded RheumNow coverage of ACR17. All content chosen by RheumNow Faculty https://t.co/cnBu3ZGJIn
— Dr. John Cush (@RheumNow) November 5, 2017
PsA&PSO decreased by half in gastric bypass pts. No such effect w/Gastric banding #ACR17 #YearInReview @RheumNow pic.twitter.com/HPTUmsC0GF
— Olga Petryna (@DrPetryna) November 5, 2017
#ACR17 #618 2year FUTURE2: 75-84% pts archive acr70 at wk24 & maintain or improve at wk104 on Cosentyx @RheumNow pic.twitter.com/CebaLMRwPr
— Olga Petryna (@DrPetryna) November 5, 2017
#ACR17 metaanalysis:Adding MTX to TNFi helps skin scores NOT joints in pts w/PsA @rheumnow #636 pic.twitter.com/2vAQgnYZXp
— k dao (@KDAO2011) November 5, 2017
Really interesting data about the effect of anti-IL-17 in depression/anxiety. There is a biological basis for this #ACR17 @RheumNow #607 pic.twitter.com/4FpW5uDVjl
— Philip Robinson (@philipcrobinson) November 5, 2017
Mease et al shows consentyx inhibits xray progression in Future5 996 PsA trial w 24wk outcomes pic.twitter.com/qJqMZMulhP
— Dr. John Cush (@RheumNow) November 5, 2017
My approach:
If primary nonresponse to TNFi -> IL-17.
If secondary nonresponse to TNFi -> 2nd TNFi#ACR17
— Dr. Paul Sufka (@psufka) November 4, 2017
ACR 2016 treatment guidelines for AS/SpA #ACR17 pic.twitter.com/c1kKEMtgKV
— Suleman Bhana, MD (@DrBhana) November 4, 2017
Top Influencers of #ACR17: @acrheum @novartis @arthritisfdn @sereumatologia @abbvie @panlarleague @emeunet More 📊 https://t.co/1Zy1ZZSVFU
— Symplur Hashtags (@healthhashtags) November 3, 2017